T1	Modifier 53 63	pathogenic
E1	Modifier:T1 
T2	Or 64 66	or
E2	Or:T2 
T3	Assertion 67 73	likely
E3	Assertion:T3 
A1	Assertion-Type-Value E3 possible
T4	Condition 74 99	pathogenic PCDH19 variant
E4	Condition:T4 Name:T56
T5	Condition 105 132	Failure to control seizures
E5	Condition:T5 Name:T57
T6	Eq-Comparison 133 150	despite 2 or more
E6	Eq-Comparison:T6 Value:T58 Operator:T59
T7	Condition 151 163	anti-seizure
E7	Condition:T7 
T8	Drug 164 175	medications
E8	Drug:T8 
T9	Condition 184 192	seizures
E9	Condition:T9 Name:T62
T10	Temporal-Connection 193 197	over
E10	Temporal-Connection:T10 
A2	Temporal-Connection-Type-Value E10 during
T11	Eq-Comparison 200 207	12-week
E11	Eq-Comparison:T11 
T12	Condition 218 233	primary seizure
E12	Condition:T12 Name:T63
T13	Temporal-Connection 240 248	prior to
E13	Temporal-Connection:T13 
A3	Temporal-Connection-Type-Value E13 before
T14	Study 249 258	screening
E14	Study:T14 
T15	Procedure 287 310	anti-seizure treatments
E15	Procedure:T15 
T16	Procedure 312 334	Vagus nerve stimulator
E16	Procedure:T16 Name:T67
T17	Procedure 336 350	ketogenic diet
E17	Procedure:T17 
T18	Or 352 355	and
E18	Or:T18 
T19	Procedure 365 376	Atkins diet
E19	Procedure:T19 
T20	Assertion 377 386	should be
E20	Assertion:T20 
A4	Assertion-Type-Value E20 hypothetical
T21	Eq-Comparison 401 409	3 months
E21	Eq-Comparison:T21 Value:T70 Temporal-Unit:T71
T22	Temporal-Connection 410 418	prior to
E22	Temporal-Connection:T22 
A5	Temporal-Connection-Type-Value E22 before
T23	Study 419 428	screening
E23	Study:T23 
T24	Eq-Comparison 455 463	Previous
E24	Eq-Comparison:T24 Temporal-Period:T72
T25	Drug 476 486	ganaxolone
E25	Drug:T25 Name:T73
T26	Eq-Comparison 492 513	> 8 consecutive weeks
E26	Eq-Comparison:T26 Operator:T74 Value:T75 Temporal-Unit:T76
T27	Observation 517 532	seizure freedom
E27	Observation:T27 
T28	Temporal-Connection 533 539	during
E28	Temporal-Connection:T28 
A6	Temporal-Connection-Type-Value E28 during
T29	Eq-Comparison 544 552	12 weeks
E29	Eq-Comparison:T29 Value:T78 Temporal-Unit:T79
T30	Temporal-Connection 553 561	prior to
E30	Temporal-Connection:T30 
A7	Temporal-Connection-Type-Value E30 before
T31	Study 562 571	screening
E31	Study:T31 
T32	Eq-Comparison 577 587	Concurrent
E32	Eq-Comparison:T32 Temporal-Period:T80
T33	Drug 595 610	strong inducers
E33	Drug:T33 Name:T81
T34	Or 611 613	or
E34	Or:T34 
T35	Drug 614 624	inhibitors
E35	Drug:T35 Name:T82
T36	Drug 628 638	CYP3A4/5/7
E36	Drug:T36 Name:T83
T37	Negation 642 645	not
E37	Negation:T37 
T38	Eq-Comparison 661 664	Use
E38	Eq-Comparison:T38 Temporal-Period:T84
T39	Drug 668 688	tetrahydrocannabinol
E39	Drug:T39 Name:T85
T40	Drug 690 693	THC
E40	Drug:T40 Name:T86
T41	Or 695 697	or
E41	Or:T41 
T42	Modifier 698 710	non-approved
E42	Modifier:T42 
T43	Drug 711 722	cannabidiol
E43	Drug:T43 Name:T87
T44	Drug 724 727	CBD
E44	Drug:T44 
T45	Negation 732 742	prohibited
E45	Negation:T45 
T46	Temporal-Connection 743 749	during
E46	Temporal-Connection:T46 
A8	Temporal-Connection-Type-Value E46 during
T47	Modifier 754 766	double-blind
E47	Modifier:T47 
T48	Other 794 799	other
E48	Other:T48 
T49	Study 800 815	investigational
E49	Study:T49 
T50	Drug 816 820	drug
E50	Drug:T50 
T51	Eq-Comparison 821 835	within 30 days
E51	Eq-Comparison:T51 Operator:T88 Value:T89 Temporal-Unit:T90
T52	Or 836 838	or
E52	Or:T52 
T53	Eq-Comparison 839 862	fewer than 5 half-lives
E53	Eq-Comparison:T53 Operator:T92 Value:T93 Temporal-Unit:T94
T54	Temporal-Connection 863 871	prior to
E54	Temporal-Connection:T54 
A9	Temporal-Connection-Type-Value E54 before
T55	Study 872 881	screening
E55	Study:T55 
T56	Condition-Name 74 99	pathogenic PCDH19 variant
T57	Condition-Name 116 132	control seizures
T58	Eq-Value 141 142	2
T59	Eq-Operator 143 150	or more
A10	Eq-Operator-Value T59 GTEQ
T60	Drug-Name 151 175	anti-seizure medications
T61	Eq-Value 181 183	12
T62	Condition-Name 184 192	seizures
T63	Condition-Name 218 233	primary seizure
T64	Eq-Temporal-Period 264 266	On
A11	Eq-Temporal-Period-Value T64 present
T65	Stability 269 275	stable
A12	Stability-Value T65 stable
T66	Drug-Name 287 310	anti-seizure treatments
T67	Procedure-Name 312 334	Vagus nerve stimulator
T68	Drug-Name 336 350	ketogenic diet
T69	Drug-Name 365 376	Atkins diet
T70	Eq-Value 401 402	3
T71	Eq-Temporal-Unit 403 409	months
A13	Eq-Temporal-Unit-Value T71 month
T72	Eq-Temporal-Period 455 463	Previous
A14	Eq-Temporal-Period-Value T72 past
T73	Drug-Name 476 486	ganaxolone
T74	Eq-Operator 492 493	>
A15	Eq-Operator-Value T74 GT
T75	Eq-Value 494 495	8
T76	Eq-Temporal-Unit 508 513	weeks
A16	Eq-Temporal-Unit-Value T76 week
T77	Condition-Name 517 532	seizure freedom
T78	Eq-Value 544 546	12
T79	Eq-Temporal-Unit 547 552	weeks
A17	Eq-Temporal-Unit-Value T79 week
T80	Eq-Temporal-Period 577 587	Concurrent
A18	Eq-Temporal-Period-Value T80 present
T81	Drug-Name 595 610	strong inducers
T82	Drug-Name 614 624	inhibitors
T83	Drug-Name 628 638	CYP3A4/5/7
T84	Eq-Temporal-Period 661 664	Use
A19	Eq-Temporal-Period-Value T84 present
T85	Drug-Name 668 688	tetrahydrocannabinol
T86	Drug-Name 690 693	THC
T87	Drug-Name 711 722	cannabidiol
T88	Eq-Operator 821 827	within
A20	Eq-Operator-Value T88 LTEQ
T89	Eq-Value 828 830	30
T90	Eq-Temporal-Unit 831 835	days
A21	Eq-Temporal-Unit-Value T90 day
T91	Eq-Operator 836 844	or fewer
A22	Eq-Operator-Value T91 GTEQ
T92	Eq-Operator 845 849	than
A23	Eq-Operator-Value T92 GT
T93	Eq-Value 850 851	5
T94	Eq-Temporal-Unit 852 856	half
A24	Eq-Temporal-Unit-Value T94 minute
